<DOC>
	<DOCNO>NCT00103246</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use drug becomes active expose certain kind light . When drug active , tumor cell kill . Photodynamic therapy use silicon phthalocyanine 4 may effective skin cancer . PURPOSE : This phase I trial study side effect best dose photodynamic therapy use silicon phthalocyanine 4 treating patient actinic keratosis , Bowen 's disease , skin cancer , stage I stage II mycosis fungoides .</brief_summary>
	<brief_title>Photodynamic Therapy Using Silicon Phthalocyanine 4 Treating Patients With Actinic Keratosis , Bowen 's Disease , Skin Cancer , Stage I Stage II Mycosis Fungoides</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose photodynamic therapy use topically deliver silicon phthalocyanine 4 patient actinic keratosis , Bowen 's disease , squamous cell basal cell skin cancer , stage IA , IB , IIA , IIB mycosis fungoides . - Determine safety toxicity therapy emphasis whether induces photosensitivity non-treated site patient . - Determine antitumor mechanism therapy , monitor tissue change via clinical , histological , immunohistochemical , biochemical marker , patient . - Determine , preliminarily , dose therapy result high clear rate patient . OUTLINE : This dose-escalation study . Patients receive topical silicon phthalocyanine 4 ( Pc 4 ) . One hour later , patient undergo photodynamic therapy . Treatment repeat weekly 3 week ( 3 total treatment lesion OR 3 lesion treat multiple lesion present ) . Cohorts 3 patient receive escalate dos Pc 4 visible light maximum tolerate dose ( MTD ) determine . The MTD define dose precede 1 3 patient experience dose-limiting toxicity . Three additional patient treat MTD . After completion study therapy , patient follow 2 week . PROJECTED ACCRUAL : A total 16-45 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Silicon phthalocyanine</mesh_term>
	<mesh_term>Silicon</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Actinic keratosis Bowen 's disease Squamous cell skin cancer Basal cell skin cancer Clinical stage IA , IB , IIA , IIB mycosis fungoides Fitzpatrick skin type IIV PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No diabetes mellitus No known hypersensitivity ethanol propylene glycol No significant history photosensitivity , include diagnosis following : Porphyria Lupus erythematosus Xeroderma pigmentosum Severe polymorphous light eruption Solar urticaria PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy More 2 week since prior anticancer radiotherapy No concurrent radiotherapy Surgery Lesions must heal prior biopsy Other More 2 week since prior topical , local , systemic anticancer therapy More 2 week since prior anticancer phototherapy More 2 week since prior photosensitizing medication , include follow : Tetracyclines Quinolones Psoralens Hydrochlorothiazide Furosemide Trimethoprimsulfamethoxazole Griseofulvin Nalidixic acid Amiodarone Phenothiazines Highdose nonsteroidal antiinflammatory drug No concurrent photosensitize medication No concurrent therapeutic dose warfarin may cause excessive bleeding skin biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>skin cancer</keyword>
	<keyword>squamous cell carcinoma skin</keyword>
	<keyword>basal cell carcinoma skin</keyword>
	<keyword>recurrent skin cancer</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>actinic keratosis</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>